Veridex Completes Acquisition of Immunicon Corporation Assets

Share Name	Share Symbol	Market	Type
Immunicon (MM)	NASDAQ:IMMC	NASDAQ	Common Stock

Share Name

Share Symbol

Market

Type

Immunicon (MM)

NASDAQ:IMMC

NASDAQ

Common Stock

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

0.19

01:00:00

Veridex Completes Acquisition of Immunicon Corporation Assets

01/08/2008 9:11pm

PR Newswire (US)

Immunicon (NASDAQ:IMMC)
Historical Stock Chart

From Jun 2019 to Jun 2024

RARITAN, N.J., Aug. 1 /PRNewswire/ -- Veridex, LLC announced today it has completed its previously announced acquisition of substantially all of the assets of Immunicon Corporation (OTC:IMMC) (BULLETIN BOARD: IMMC) and its wholly-owned subsidiaries. The assets acquired include intellectual property, product inventory and clinical data as well as all technologies related to the CellSearch(TM) System, the first diagnostic test to automate the detection and enumeration of circulating tumor cells (CTCs), cancer cells that detach from solid tumors and enter the blood stream. The CellSearch(TM) System is currently cleared for the prognosis and monitoring of patients with metastatic breast, metastatic colorectal and metastatic prostate cancer. As part of the agreement, Veridex also received all technologies related to Repeat-Free(TM) (RF) Poseidon(TM) Fluorescent In-Situ Hybridization (FISH) Probes, which are the latest advance in FISH DNA probes. "This asset purchase ensures the role of CellSearch(TM) in the future of Veridex," said Ken Berlin, General Manager, Veridex, LLC. "It underscores our continued commitment to the medical community and to cancer patients who may benefit from technologies like the CellSearch(TM) System." Veridex and Immunicon have partnered since 2000 to develop and commercialize novel cancer diagnostic platforms and products. About Veridex Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value in vitro diagnostic oncology products. Veridex's products may significantly benefit patients through earlier disease detection and may enable personalized strategies to help improve patient management and outcomes. For more information, please visit http://www.veridex.com/. DATASOURCE: Veridex, LLC CONTACT: Media, Stephanie Fagan, +1-201-572-9581, or Investor, Louise Mehrotra, +1-732-524-6491, or Stan Panasewicz, +1-732-524-2524, all for Veridex, LLC Web site: http://www.veridex.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

IMMC Immunicon (MM)